Neurobiology of tau protein: regulation and deregulation in vivo
Alzheimer’s disease (AD) is the leading form of dementia. The neuropathological hallmarks of Alzheimer’s disease include senile plaques of β-amyloid (Aβ) peptides (a cleavage product of the Amyloid Precursor Protein, or APP), and neurofibrillary tangles (NFT) of hyperphosphorylated tau protein assembled in paired helical filaments (PHF). NFT pathology is important, since it correlates with the degree of cognitive impairment in AD. Our laboratory focuses on understanding the causes and consequences of tau pathology.
We focus on 3 main research directions, performed mainly in vivo, with the help of transgenic mouse models of AD:
Molecular basis of tau regulation in vivo
Hyperphosphorylation of tau by deregulation of kinases and/or phosphatases has been proposed to dissociate tau from microtubules (MTs), thereby destabilizing the MTs and disrupting MT dependent axonal transport. Thus, we are studying the regulation of tau phosphorylation, tau splicing, and of tau toxicity and aggregation.
Impact of biological and environmental factors on AD pathogenesis
Only a small proportion of AD is due to genetic variants, the large majority of cases (~95%) is late onset and sporadic in origin. The cause of sporadic AD is likely to be multifactorial, with external factors interacting with biological or genetic susceptibilities to accelerate the manifestation of the disease. Here, we study the impact of genetic and biological susceptibilities such as aging, diabetes, inflammation, and external factors, such as anesthesia and trauma, on the development of tau pathology.
Pharmacological treatments of AD pathology
Targeting tauopathy with pharmacological compounds to alleviate the symptoms of AD is a growing field of research. We have been conducting research studying the impact of kinase inhibitors, as well as MT stabilizing drugs on tau pathology in vivo. We have now developed collaborations to study the effects of new compounds, and new therapeutic approaches.
All our research would not be possible without the support and generosity of the Alzheimer’s Society of Canada, the CIHR, the NSERC, the FRSQ, the RQRV, and AFIRMAQ.
2705, boulevard Laurier
Canada G1V 4G2
Data not available
- Guisle, IsabelleDoctoral studentCHUL+1 418-525-4444, extension email@example.com
2705 Boul Laurier Local P-09800
Canada G1V 4G2
- Lerdu, OphélieMaster firstname.lastname@example.org
- Morin, FrançoiseEmployeeCHUL+1 418-525-4444, extension 47532+1 418-525-4444, extension 47908+1 418-654-2753Francoise.Morin@crchudequebec.ulaval.ca
2705, boulevard Laurier
Canada G1V 4G2
Administration of the benzodiazepine midazolam increases tau phosphorylation in the mouse brain.Journal Article
Neurobiol Aging, 75 , pp. 11-24, 2018, ISSN: 0197-4580.
Co-occurrence of mixed proteinopathies in late-stage Huntington's disease.Journal Article
Acta Neuropathol, 135 (2), pp. 249-265, 2018, ISSN: 0001-6322.
Human Tau Expression Does Not Induce Mouse Retina Neurodegeneration, Suggesting Differential Toxicity of Tau in Brain vs. Retinal Neurons.Journal Article
Front Mol Neurosci, 11 , pp. 293, 2018.
Corrigendum: Human Tau Expression Does Not Induce Mouse Retina Neurodegeneration, Suggesting Differential Toxicity of Tau in Brain vs. Retinal Neurons.Journal Article
Front Mol Neurosci, 11 , pp. 390, 2018.
Presence of tau pathology within foetal neural allografts in patients with Huntington's and Parkinson's disease.Journal Article
Brain, 140 (11), pp. 2982-2992, 2017, ISSN: 0006-8950.
- Centre hospitalier universitaire de Québec - CHU de Québec-Université Laval, Subvention, Centre hospitalier universitaire de Québec - Université Laval, Centres de recherche affiliés, from 2017-01-01 to 2099-12-31
- Centre thématique de recherche en neurosciences, Subvention, Institutionnel - BDR, BDR - Centres de recherche reconnus, from 1999-06-01 to 2020-10-18
- Regulation of tau phosphorylation and splicing during post-embryonic development., Subvention, Conseil de recherches en sciences naturelles et génie Canada, Subventions à la découverte SD (individuelles et d'équipe), from 2016-04-01 to 2021-03-31
Recently finished projects
- Anesthesia and Alzheimer's disease pathogenesis, Subvention, Fonds de recherche du Québec - Santé, Chercheur-boursier Juniors 1 et 2, Seniors, from 2013-07-01 to 2017-06-30
- Effects of perioperative factors on tau pathogenesis, Subvention, Société Alzheimer du Canada, Subventions de recherche, from 2016-07-01 to 2018-12-31
- Investigating a potential role for the microtubule stabilizing protein Tau in cancer, Subvention, Fondation de l'Université Laval, from 2016-09-15 to 2018-09-14
- Molecular and Biological Characterisation of Novel Genetic Markers Associated to the Common of Alzheimer's disease in a Population isolate from Eastern Canada., Subvention, Instituts de recherche en santé du Canada, Subvention de fonctionnement, from 2012-01-01 to 2017-03-31
- New delta ribozymes targeting tau mRNA as therapeutics for FTD., Subvention, Fondation de l'Université Laval, from 2015-10-01 to 2017-09-30
- Tau protein in neurobiology: regulation and deregulation in vivo., Subvention, Instituts de recherche en santé du Canada, Bourse salariale pour nouveau chercheur, from 2013-07-01 to 2018-06-30
- The role of apoE in mild traumatic brain injury., Subvention, Instituts de recherche en santé du Canada, Subvention de fonctionnement, from 2012-10-01 to 2017-09-30